Liquid Biopsy in Cancer Screening: An Evidence-Based Review for Clinicians

Abstract

Liquid biopsy is revolutionizing the landscape of cancer screening by enabling the detection of tumor-derived biomarkers in body fluids, primarily blood. This minimally invasive technique offers the promise of early detection, disease monitoring, and therapeutic guidance across multiple cancer types. Recent advances in analytical sensitivity and specificity have driven its adoption in both research and clinical settings. This review synthesizes current evidence regarding the role of liquid biopsy in cancer screening, elucidates its pathophysiological basis, evaluates clinical applications, and discusses emerging technologies and guideline recommendations relevant to practicing clinicians.

Introduction

Cancer screening has traditionally relied on imaging and tissue biopsies, which, although effective, present limitations such as invasiveness, sampling errors, and delayed detection. Liquid biopsy has emerged as a transformative approach that utilizes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other tumor-derived components present in blood and other body fluids. This review aims to provide physicians and healthcare professionals with a comprehensive, evidence-based overview of liquid biopsy in cancer screening, focusing on its clinical relevance, current limitations, and future potential.

Epidemiology / Disease Burden

Cancer remains a leading cause of morbidity and mortality worldwide, with an estimated 19.3 million new cases and 10 million deaths in 2020 alone (Globocan 2020). Early detection is critical, as survival rates are significantly higher for cancers identified at an early stage. However, conventional screening methods fail to capture all at-risk individuals, particularly for malignancies such as pancreatic, ovarian, and lung cancers, where early-stage diagnosis is challenging. The advent of liquid biopsy offers a promising adjunct or alternative for improving screening efficacy and reducing the global cancer burden.

Pathophysiology

Liquid biopsy capitalizes on the pathophysiological processes underlying tumorigenesis. Tumors shed nucleic acids (ctDNA, miRNA), proteins, and whole cells (CTCs) into the bloodstream. ctDNA, often harboring tumor-specific mutations, reflects the genetic landscape of the primary tumor and its metastases. Exosomes and microvesicles contain proteins and nucleic acids that mirror the tumor microenvironment. These circulating biomarkers can be detected and quantified using next-generation sequencing, digital PCR, and other highly sensitive molecular assays, enabling the detection of minute amounts of tumor material even in asymptomatic individuals.

Risk Factors

The utility of liquid biopsy is particularly pronounced in high-risk populations. Individuals with hereditary cancer syndromes (e.g., BRCA mutations), significant family history, occupational exposures, and lifestyle factors (such as smoking) are prime candidates for enhanced surveillance. Liquid biopsy can complement traditional risk stratification tools by providing molecular evidence of early neoplastic changes, thereby facilitating personalized screening strategies.

Clinical Features

Unlike conventional tissue biopsies, liquid biopsies do not directly reveal clinical features but enable the identification of molecular alterations before the onset of symptoms. For cancers such as lung, colorectal, and breast cancer, liquid biopsy can detect actionable mutations, gene fusions, and methylation patterns associated with tumorigenesis. This molecular information can precede clinical manifestations, supporting the rationale for incorporating liquid biopsy into screening protocols for at-risk, asymptomatic individuals.

Diagnosis

Liquid biopsy is increasingly being integrated into diagnostic workflows. ctDNA analysis allows the non-invasive detection of tumor-specific mutations such as EGFR in lung cancer and KRAS in colorectal cancer. Sensitivity and specificity vary by cancer type and stage, with advanced tumors shedding more detectable material. For early-stage cancers, multi-analyte tests combining ctDNA, protein markers, and methylation signatures have improved diagnostic accuracy. Importantly, liquid biopsy can also serve as a tool for identifying minimal residual disease (MRD) post-treatment, offering a means for monitoring recurrence.

Treatment & Management

Beyond screening, liquid biopsy informs therapeutic decision-making by identifying actionable mutations and resistance mechanisms. In clinical practice, positive liquid biopsy findings can prompt confirmatory imaging or tissue biopsy, guide targeted therapy selection, and allow for dynamic monitoring of treatment response. For example, serial ctDNA measurements can track clonal evolution and emergence of resistance mutations, enabling timely modifications in therapeutic strategy. This real-time molecular monitoring represents a paradigm shift in personalized oncology care.

Recent Advances / Emerging Therapies

Recent years have witnessed significant technical advancements in liquid biopsy platforms. Ultra-sensitive assays now enable the detection of single mutant molecules amidst a vast background of normal DNA. Multi-cancer early detection (MCED) tests analyze methylation patterns across dozens of cancer types from a single blood draw, with several large-scale trials demonstrating promising results in sensitivity and specificity. Additionally, the integration of artificial intelligence and machine learning has improved the interpretation of complex biomarker data, enhancing predictive accuracy and clinical utility. Ongoing research is exploring the application of liquid biopsy to immunotherapy monitoring and the detection of therapeutic resistance at an earlier stage than conventional imaging.

Guideline Recommendations

While liquid biopsy is rapidly gaining traction, its routine use in population-wide cancer screening is not yet universally endorsed. Current guidelines from organizations such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) recommend liquid biopsy primarily for specific indications, such as the identification of actionable mutations in advanced non-small cell lung cancer and the assessment of MRD in colorectal cancer. However, ongoing large-scale studies may soon provide the evidence needed to expand these recommendations, particularly as multi-cancer screening tests become more robust and cost-effective.

Conclusion

Liquid biopsy represents a major advancement in the field of oncology, offering a minimally invasive approach to cancer screening, diagnosis, and management. Its ability to detect tumor-derived biomarkers with high sensitivity and specificity has the potential to transform early detection paradigms and personalize patient care. While challenges remain regarding standardization, cost, and integration into screening programs, the evolving evidence base supports a growing role for liquid biopsy in clinical practice. Continued research and the refinement of guidelines are expected to further define its optimal use, ultimately improving cancer outcomes across diverse patient populations.